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Purpose: Bacterial burden on the eyelid margin and within meibomian glands was evaluated for inﬂuence on speciﬁc ocular surface disease (OSD) markers across the meibomian
gland dysfunction (MGD) spectrum.
Methods: In this prospective, observational, single-center study, 40 patients were divided
into 4 equal groups of 10 that encompassed increasingly worse MGD/OSD categories. All
patients answered the standard Ocular Surface Disease Index questionnaire, and underwent
tear osmolarity testing (TOT), Schirmer 1, matrix metalloproteinase 9 (MMP-9) testing,
meibography, and lissamine green staining. Cultures of eyelid margins and meibomian gland
secretions were directly plated on blood, chocolate, and Sabouraud agar; smears were sent
for gram and Papinicolau evaluation.
Results: Mean patient age was 55.25±17.22 years; there were 10 males and 30 females.
TOT and MMP-9 testing were similar across groups. Culture positivity was 62.5% for right
eyes, 70% for left eyes, and was not statistically different across groups (for both eyelid
margin and meibomian glands). The majority of cultures were positive for coagulasenegative staphylococcus (CNS).
Conclusion: This study is in concordance with others, citing the predominance of CNS
within the bioﬁlm of both “normal” and clinically signiﬁcant MGD/OSD patients. Our study
exempliﬁes that symptoms of OSD do not necessarily correlate with degree of clinical exam
ﬁndings, nor culture positivity. These results argue that bacterial burden should be reconsidered as a direct risk factor and treatment target for MGD/OSD patients.
Keywords: blepharitis, bioﬁlm, dry eye, meibomian gland dysfunction, ocular surface
disease
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Meibomian glands are modiﬁed sebaceous glands that are arranged vertically in the
tarsal plate.1 With each blink, meibum is released and interacts with the tear ﬁlm to
create a smooth refractive surface and maintain consistent quality of vision.1
Patients with meibomian gland dysfunction (MGD) suffer visual consequences
secondary to tear ﬁlm instability, reduced tear break up time and evaporative dry
eye.1 In the early stages of MGD, patients may be asymptomatic – but if left
untreated, it will either cause or exacerbate dry eye symptoms (dryness, burning,
itching, foreign body sensation, photophobia, tearing, intermittent blurred vision).1
MGD, blepharitis, and dry eye disease are overlapping and challenging entities to
treat, secondary to lack of a single evident treatment target. Multiple studies have
linked imbalance in the bacterial ﬂora with blepharitis and MGD – however, it is
unclear if the bacteria cause MGD, if MGD allows for bacterial overgrowth, or if
Clinical Ophthalmology 2019:13 1225–1234
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speciﬁc factors released from the bacteria (eg, lipases) lead to
meibomian gland inspissation, plugging and disruption of
normal gland and eyelid physiology.1–14 In this light, antibiotics, speciﬁcally macrolides (eg, azithromycin, erythromycin), ﬂuoroquinolones and tetracyclines (eg, doxycycline)
have been studied for their efﬁcacy and mechanism of action
in treating MGD.1,3,4,5,8–11 In concert with this, studies have
demonstrated the predominant organisms that live on the
eyelids. Presence of coagulase-negative staphylococcus
(CNS) (eg, Staphylococcus epidermidis), Staphylococcus
aureus, Corynebacterium, and Propionibacterium acne, has
been delineated in “normal” patients and those with
blepharitis.8,9,10,15–20
Slit lamp examination and use of vital dyes, such as
lissamine green have historically allowed for delineation
of the extent of ocular surface disease (OSD). Additionally,
the ophthalmologist has an armamentarium of diagnostic
tests available to evaluate dry eye – whether evaporative or
aqueous-deﬁcient in nature. For example, there is testing
available for the inﬂammatory marker matrix metalloproteinase-9 (MMP-9) presence in the tears, suggesting that
these patients with positive tests may respond favorably to
anti-inﬂammatory therapy.6 High tear osmolarity levels
suggest aqueous deﬁciency.6,20 Meibography may also be
used for evaluation of patients with MGD/dry eye, as meibomian gland loss (“drop-out”) has been signiﬁcantly correlated to dry eye and evaporative tear ﬁlm dysfunction.12,20
In concert with this, Schirmer 1 testing may be used to
evaluate aqueous tear deﬁciency.20
We now know that various resident species of bacteria
on the eyelids may be implicated in either the etiology or
propagation of MGD.8,9,10,15–19 To date, no studies have
been performed evaluating the correlation of bacterial
burden on speciﬁc dry eye/OSD markers (ie, tear osmolarity, Schirmer tests, meibography, or MMP-9 positivity).
These tests, in conjunction with slit lamp examination and
corneal staining, are important indicators of the type of dry
eye a patient has, and the direction in which treatment
should be guided. In addition, comparison of eyelid/meibomian gland bacterial burden across disease spectrum (ie,
normal, asymptomatic, subclinical, and clinically signiﬁcant meibomian gland dysfunction patients) on the forementioned diagnostic parameters has not been described.
In completion of this study, the goals were to establish
relationships between bacterial culture positivity (of eyelid
margin, meibomian glands) and degree of OSD and MGD
as elucidated on clinical exam and by a variety of in-ofﬁce
diagnostic tests.
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Methods
Before commencement of the study, study protocols, consent forms, and data accumulation methods were approved
by the Institutional Review Board of NuHealth (Nassau
University Medical Center, East Meadow, NY). Written
informed consent was obtained from each patient at
screening and Health Insurance Portability and
Accountability Actregulations were followed. The study
was conducted according to the tenets of the Declaration
of Helsinki.
This was a prospective observational study comprised
of 40 patients (80 eyes) in a single practice setting. The
study was comprised of four equal groups (“A,B,C,D”) of
patients, who underwent evaluation for signs and symptoms of dry eye and meibomian gland dysfunction.
Inclusion criteria were 18 years old or older, and the
ability to consent for eye exam, including routine diagnostic procedures related to dry eye evaluation. Exclusion
criteria were pregnancy, inability to consent, age <18
years old, active ocular infection, and current use of antibiotic and/or antifungal medications (topical or systemic).
The examined patients were assigned to one of the four
groups based upon Ocular Surface Disease Index (OSDI)
score and degree of meibomian gland disease present on
examination.
Group A served as controls. The majority of these
patients’ visits were for routine eye exams without frank
evidence of dry eye and/or MGD on exam. These patients
had an OSDI score of 0–40. Group B were “asymptomatic”
patients with little-to-no complaints of eye discomfort but
had exam components suggestive of mild dry eye/MGD,
with an OSDI score of 50 or below. Group C were those
patients who had “subclinical disease”. These patients had
occasional complaints consistent with OSD (eg, dryness,
irritation, redness) with evidence of mild-moderate dry eye
and/or MGD on exam, as well as an OSDI score of 63 or
below. Group D consisted of patients with clinically signiﬁcant meibomian gland dysfunction/OSD. These patients
had symptoms of near-constant burning/irritation/dryness,
etc., as well as evidence of signiﬁcant disease (eg, meibomian gland plugging, dropout, positive dry eye markers) on
exam, and an OSDI score of 100 or below.

Evaluation
Each patient in the study had both eyes evaluated. Patient
complaints were recorded and all underwent standard slit
lamp examination. All patients had cultures and sensitivities
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of their eyelid margin and meibomian gland secretions. All
participants answered a standard OSDI Questionnaire©.21
In addition to the questionnaire, each subject underwent comprehensive evaluation of past medical/ocular
history. Uncorrected (UCVA) and best-corrected (BCVA)
visual acuity was measured using the Snellen chart.
Comprehensive slit lamp examination was performed, noting the presence and grade of meibomian gland dysfunction, drying of the ocular surface, eyelid irregularities, and
tear breakup time. Grading of meibomian gland dysfunction (ease of expression and type of secretions) was performed according to the International Workshop on
Meibomian Gland Dysfunction.5
Tear osmolarity testing (TOT) was performed using the
standard TearLab® (San Diego, CA, USA) system. MMP9 testing was performed using the standard Inﬂammadry®
(Rapid Pathogen Screening, Sarasota, FL, USA) system.
Schirmer I testing was performed in the standard manner
(ie, without anesthetic) for both eyes. Meibography was
performed to evaluate meibomian gland status/dropout
using the Oculus Keratograph® system (Oculus,
Arlington, WA, USA). Comparison of dropout in the
right upper and lower, as well as left upper and lower
lids was performed across groups. Results were graded
via the Meiboscale and degree of meibomian gland loss
was converted into percentages for data analysis.19
Gradation of lissamine green staining of the conjunctiva
and cornea was performed for each eye according to the
Oxford Grading System (scale 0 through 4, with 0 equating
to no staining and 4 meaning dense, conﬂuent staining).
Cultures of the eyelid margin were performed using platinum
spatula by gently scraping the eyelid margin, and sent for
evaluation on blood, Sabouraud, and chocolate agar plates.
Meibomian gland secretions were obtained by applying pressure to the eyelid margin with two cotton-tipped applicators,
one on the outer eyelid, one in the fornix, after application of
a topical anesthetic. Secretions were plated directly from the
cotton-tip applicator containing meibum onto the culture
plates. Scraping from the eyelid margin and meibum from
meibomian gland expression was directly applied to a glass
cytology slide, which was immediately ﬁxed in methanol.
These slides were sent for gram stain and cytology studies.
Primary outcome measures were degree of bacterial
burden (ie, culture positivity as well as sensitivity studies)
and culture results as correlated with dry eye and meibomian gland dysfunction diagnostic parameters.
Secondary outcome measures were comparison of culture and testing results between eyes, comparison of
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culture and testing results across the spectrum of dry
eye/meibomian gland dysfunction, comparison of OSDI
questionnaire responses with exam ﬁndings, testing and
culture results, as well as analysis of demographic variables (eg, age, sex) on culture results, OSDI responses,
exam ﬁndings and diagnostic testing results.

Statistical considerations
Study variables were analyzed by appropriate statistical
methods to assess for the differences among the four
groups. Correlation between testing parameters, meibomian
gland dropout, ocular surface staining, culture, gram stain
and cytology positivity between groups, and demographics
were assessed using ANOVA, chi-square (χ2), Student's ttest, and the Fisher z-transformation test. p-values less than
or equal to 0.05 were considered statistically signiﬁcant.

Results
Overall ﬁndings and correlation with
culture positivity
Forty patients from October 2016 through March 2017
were evaluated in a single practice setting. Mean patient
age was 55.25±17.22 years (range 18–81); there were 10
males and 30 females. When evaluating age in respect to
results, the patients in the control group were younger
(40.7±12.27); this was statistically signiﬁcant (ANOVA,
p=0.014).
All patients completed an OSDI survey. Overall mean
OSDI score was 36.16±19.45 (range 6–75). As shown in
Figure 1, mean OSDI scores were increasingly worse from
Group A (19.73±8.43) to B (31.355±7.81), to C (39.08
±11.586) to D (54.46±15.054); this was statistically signiﬁcant
(ANOVA; p<0.001). OSDI score across groups was not statistically correlated with positive lid (t-test, p=0.686 OD and
p=0.463 OS) or meibomian gland (t-test, p=0.769 OD and
p=0.765, respectively) cultures.
Mean TOT OD was 302.05±13.59; OS was 301.5
±15.18. TOT score was not statistically signiﬁcant across
groups or eyes (ANOVA, p=0.977 and p=0.819, respectively). When comparing TOT results versus eyelid margin
culture positivity (OD and OS), no statistical relationship
was found (t-test, p=0.630 and p=0.673, respectively). No
statistical relationship was found with TOT results and
meibomian gland culture positivity (OD or OS) (t-test,
p=0.873 and p=0.87, respectively)
Thirty-seven and one-half percent of right eyes were
MMP-9 positive; 47.5% of left eyes were MMP-9
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Meibography RLL
by group

A
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A

28.5 ± 13.174

B

31.355 ± 7.814

B

32 ± 13.51

C

39.08 ± 11.586
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34.5 ± 11.114

D

54.46 ± 15.054

D

59.5 ± 17.959

0

10

20

30

40

50

60

Groups

Groups

OSDI Score
by group

70

0
OSDI
Score
Figure 1 Increasing Ocular Surface Disease Index (OSDI) scores by group
(ANOVA; p<0.001).

positive; however, positive results were not statistically
different across groups or eyes (χ2p=0.205; p=0.659,
respectively). MMP-9 positivity was not statistically correlated to positive eyelid (z-score, p=0.722 OD and
p=0.191 OS) or meibomian gland (z-score, p=0.752 OD
and p=0.288 OS) cultures.
Average Schirmer 1 score for OD was 16.53±15.18
(range 0–35); and 16.38±9.19 (range 0–35) OS. Schirmer
1 scores were not statistically signiﬁcantly different across
groups or eyes (ANOVA, p=0.113, p=0.200, respectively).
There was no statistical relationship found between
Schirmer 1 scores and eyelid margin (t-test, p=0.081 and
p=0.845) or meibomian gland cultures (t-test, p=0.052,
p=0.790) in right and left eyes, respectively.
Mean percentage meibomian gland dropout on meibography was 31.5±17.26 for the right upper lid (RUL), 38.63
±22.42 for the right lower lid (RLL), 31.5±18.21 for the left
upper lid (LUL) and 39.39±18.03 for the left lower lid (LLL).
Difference in gland dropout was not statistically different
across groups for the RUL (ANOVA, p=0.062); however, it
was statistically different across groups for the RLL
(ANOVA, p=0.005), with increasing amounts of dropout
from Group A through Group D. This is demonstrated in
Figure 2. Percentage gland loss was also statistically different
and worsened across Group A through Group D for the left
upper and lower eyelids (ANOVA, p=0.026 and p=0.032,
respectively). These ﬁndings are shown in Figures 3 and 4,
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Figure 2 Increasing meibomian gland loss in right lower lid (RLL) by group
(ANOVA; p=0.005).

respectively. Percentage meibomian gland loss was not statistically correlated to positive eyelid margin (t-test,
p=0.0498) or meibomian gland (t-test, p=0.451) cultures.
Mean overall lissamine green staining score for the
conjunctiva was 1.2±0.84 for the right eye and 1.29±1.03
for the left eye. Conjunctival lissamine green staining
across all groups was increasingly (and signiﬁcantly)
worse from Group A to D. As shown in Figures 5 and 6,
respectively, this was true for both right (ANOVA, p=0.004)
and left (ANOVA, p=0.041) eyes. Conjunctival lissamine
green staining was not statistically correlated with positive
eyelid margin (t-test, p=0.338 OD and p=0.070 OS) or
meibomian gland (t-test, p=0.669 OD and p=0.079 OS)
cultures.
Mean corneal lissamine green score for the right eye was
0.4±0.46 (range 0–2) and 0.45±0.49 (range 0–2), and was
not statistically different across all groups (ANOVA,
p=0.679 [OD], p=0.726 [OS]). Corneal lissamine green
staining was not statistically correlated with positive eyelid
margin (t-test, p=0.829 OD and p=0.781 OS) or meibomian
gland (t-test, p=0.395 OD and p=0.756 OS) cultures.
Mean grade of meibomian gland secretions was 3.02
±1.13 for the right eye and 3.01±1.11 for the left eye.
Gradation of meibomian gland secretions was not statistically correlated with positive eyelid margin (t-test,
p=0.198 OD and p=0.732 OS) or meibomian gland (ttest, p=0.925 OD and p=0.612 OS) cultures.
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Conjunctival lissamine grade OD by group

A

18 ± 9.266

B

35.5 ± 15.217

C

31 ± 10.228

D

41.5 ± 12.735
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Groups

Meibography LUL
by group
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Gradation of conjunctival staining

% Meibomian gland loss
Figure 3 Increasing meibomian gland loss in left upper lid (LUL) by group (ANOVA;
p=0.026).

Figure 5 Increasing conjunctival staining across groups, right eye (ANOVA;
p=0.004).

Conjunctival lissamine grade OS by group

A

32 ± 13.719

B

37 ± 11.336

C

35 ± 9.235

D

53.5 ± 13.388

Groups

Groups

Meibography LLL
by group
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0.8 ± 0.699

B

1.1 ± 0.329

C

1.2 ± 0.719

D

2.05 ± 0.899

0
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% Meibomian gland loss
Figure 4 Increasing meibomian gland loss in left lower lid (LLL) by group (ANOVA,
p=0.032).

Overall, there were 25 right eyes (62.5%) and 30 left
eyes (75%) with positive cultures. Across groups and
eyes, eyelid margin culture positivity was not statistically signiﬁcant (χ2 p=0.813 and p=0.439, respectively).
Additionally, across groups and eyes, meibomian gland
culture positivity was not statistically signiﬁcant (xχ2
p=0.380 and p=0.710, respectively).
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Figure 6 Increasing conjunctival staining across groups, left eye (ANOVA;
p=0.041).

Of those patients with positive cultures, 12 right eyes
(48%) and 19 left eyes (63%) had positive lid margin
cultures. Of those patients with positive cultures, meibomian gland cultures were positive in 13 right eyes (52%)
and 11 (36%) left eyes. Two eyes had positive gram stain
(with positive correlation with culture results); no eye had
positive cytology (Papinicolau) ﬁndings. Of all positive
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cultures, 21 right eyes (84%) and 23 left eyes (76%) were
positive for CNS, ie, S.epidermidis). Of all positive cultures, one right eye (4%) was resistant to erythromycin
(CNS) and ten (33%) left eye cultures were resistant to
erythromycin (CNS, S. aureus). Of all positive cultures,
most were susceptible to tetracycline. Two left eye cultures
(6%) were tetracycline resistant (both CNS).

Results: group breakdown/speciﬁcs
Group A results
Group A consisted of “control patients” with little-no
complaints of eye discomfort. Ten patients (20 eyes) comprised this group, with six male and four female patients.
The average age was 40.7±16.3 years; mean OSDI score
was 19.73±11.6. When comparing meibomian gland loss
in Group A versus all other groups, there was statistically
less gland dropout for the RUL (test, p=0.026) and LUL (ttest, p=0.006). Meibomian gland secretions/expression
scores were signiﬁcantly better in Group A compared
with other groups for both right (t-test, p=0.019) and left
eyes (t-test, p=0.011). Eyelid margin cultures were positive in 40% and 60% of right and left eyes, respectively.
Meibomian gland secretions were positive in 50% and
40% of right eye left eyes, respectively. Three additional
species aside from CNS were cultured (Corynebacterium
species, Candida parapsilosis, and S. aureus). Diagnostic/
testing results for this group are displayed in Table 1.

Group B results
Group B consisted of ten (one male, nine female) patients (20
eyes) with average OSDI score 31.36±10.4. Mean age was
61±12.8 years. Thirty percent of right eyelid margin samples
were culture positive; 40% of left eyelid margin samples
were culture positive. Meibomian gland secretions were
positive in 40% and 20% of right and left eyes, respectively.
There were two right eye cultures positive for organisms
other than CNS (Staphylococcus lugdunesis, S. aureus) and
one left eye culture positive for S. aureus. Diagnostic/testing
results for this group are shown in Table 2.

Group C results
Group C comprised the “subclinical meibomian gland disease” patients, with average OSDI score of 39.08±15.3.
This group had ten patients (20 eyes), two males and eight
females; average age was 61.7±12.6 years. Thirty percent
and 60% of eyelid margin cultures were positive in right and
left eyes, respectively. Meibomian gland cultures were positive in 20% of right eyes and 30% of left eyes. Three right
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Table 1 Group A results
Parameter

OD

OS

TOT
%MMP-9+

302.6±6.5
10

304.9±18.58
40

Schirmer 1 score

22.7±9.9

20.8±9.6

Conjunctival LG score
Corneal LG score

0.85±0.78
0.25±0.6

0.8±0.93
0.35±0.63

MG expression scorea

2.3±1.27a

2.25±1.17a

% Total positive cultures
% Positive lid margin culturesb

50
90%

60
100%

% Positive MG culturesb
% Positive CNSb

100%
100

66%
100

%Erythromycin resistanceb

0

33

%Tetracycline resistanceb

0

0

Notes: aStatistically signiﬁcant results for MG Expression score. bPercentage of
culture positive group.
Abbreviations: MG, meibomian gland; OD, right eye; OS, left eye; LG, lissamine green.

Table 2 Group B results
Parameter

OD

OS

TOT

303.3±18.4

298.9±11.04

%MMP-9+
Schirmer 1 score

40
15.8±10.8

40
14.9±9.3

Conjunctival LG score

1.05±0.47

1.1±0.4

Corneal LG score
MG expression score

0.5±0.55
3.3±1.04

0.6±0.58
3.4±0.92

%Total positive cultures

50

50

% Positive lid margin culturesa
% Positive MG culturesa

80
80

80
40

% Positive CNSa

100

80

%Erythromycin resistancea
%Tetracycline resistancea

0
0

30
10

Note: aPercentage of culture positive group.
Abbreviations: MG, meibomian gland; OD, right eye; OS, left eye; LG, lissamine green.

Table 3 Group C results
Parameter

OD

OS

TOT

300.6±15.03

299.2±15.6

%MMP-9+
Schirmer 1 score

50
15.1±5.6

60
17.9±6.33

Conjunctival LG score

0.9±0.5

1.2±0.9

Corneal LG score
MG expression score

0.45±0.35
3.2±0.7

0.4±0.4
3.2±0.7

% Total positive cultures

40

70

% Positive lid margin culturesa
% Positive MG culturesa

75
50

86
43

% Positive CNSa

75

71

%Erythromycin resistancea
%Tetracycline resistancea

10
0

30
10

Notes: aPercentage of culture positive group.
Abbreviations: MG, meibomian gland; OD, right eye; OS, left eye; LG, lissamine green.
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eye and two left eye cultures were positive for organisms
other than CNS (Corynebacterium species, Acinetobacter
calcoaceticus; and A. calcoaceticus, Haemophilus inﬂuenzae, respectively). Diagnostic/testing results for this group
are shown in Table 3.

Group D results
Group D comprised “clinically signiﬁcant meibomian gland
disease” patients with mean OSDI score of 54.5±19.96.
This group was composed of ten (one male, nine female)
patients (20 eyes) with an average age of 56.7±17.29 years.
When comparing Group D meibography scores to all other
groups combined, there was statistically greater percentage
gland loss in Group D for the RLL (t-test, p<0.001), LUL
(t-test, p=0.046), and LLL (t-test, p=0.003). Group D also
had statistically worse conjunctival staining OD (t-test,
p<0.001) and OS (t-test, p=0.006). Meibomian gland drop
out scores are shown in Table 5. In this group, 20% of right
eyelid margin samples were culture positive; 30% of left
eyelid margin cultures were positive. Meibomian gland
cultures were positive in 20% of both right eye left eye
samples. Two right eyes had cultures positive for organisms
other than CNS (Actinomyces species, Corynebacterium
species) and three left eyes had cultures positive for other
organisms (Stenotrophomonas maltophilia, Pantoea
agglomerans, Cladosporium species). Testing results from
Group D are shown in Table 4.

Discussion
Treatment of meibomian gland dysfunction and OSD
remains challenging, despite our array of diagnostic tests
Table 4 Group D results
Parameter

OD

TOT

301.7±11.4

301.6±13.76

%MMP-9+

50

60

Schirmer 1 score
Conjunctival LG scorea

12.5±8.5
2±0.95a

12.8±8.81
2.05±1.9a

Corneal LG score

0.4±0.2

0.45±0.27

MG expression score
% Total positive cultures

3.3±1.1
40

3.2±1.17
30

% Positive lid margin culturesb

50

100

% Positive MG culturesb
% Positive CNSb

50
25

66
66

%Erythromycin resistanceb

0

20

%Tetracycline resistanceb

0

0

a

OS

Notes: Statistically signiﬁcant results for conjunctival lissamine stain score.
b
Percentage of culture positive group.
Abbreviations: MG, meibomian gland; OD, right eye; OS, left eye; LG, lissamine green.
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Table 5 Percentage meibomian gland loss across groups
%MG loss

RUL

RLL

LUL

LLL

Group A

21
±15.13a

28.5±17.5

18±12.3a

32±18.2

Group B

36.5±20.9

32±17.9

35.5±20.2

37±15.03

Group C
Group D

29.5±10.9
40±13.78

34.5±14.7
59.5

31±13.6
41.5

35±12.2
53.5

±23.82a

±16.89a

±17.76a

Notes: aStatistically signiﬁcant results for MG loss.
Abbreviations: MG, meibomian gland; RUL, right upper lid; RLL, right lower lid;
LUL, left upper lid; LLL, left lower lid.

and ability to perform comprehensive in-ofﬁce evaluations.
As demonstrated in our results, varying culture positivity as
well as a variety of different organisms was found within and
between groups, regardless of symptoms and diagnostic testing scores. The majority of positive cultures were for CNS
and S. aureus; their presence on the skin and eyelid margin
has been well documented.1,5,9,15,16,33,34 Other organisms
found in our study, such as Corynebacterium, Bacillus,
Actinomyces, and H. inﬂuenzae have also been noted to be
present on the lid margins, however to a much lesser extent
compared to CNS and S. aureus.8,15,22–32,35
Our study demonstrated increasing OSDI scores as
degree of meibomian gland dysfunction/OSD worsened
which is not unexpected. Additionally, TOT, MMP-9, and
Schirmer testing did not signiﬁcantly change across the disease spectrum, but conjunctival lissamine green staining and
degree of meibomian gland dropout (as shown on meibography) did deteriorate in the groups with clinically signiﬁcant
disease. We think that the degree of lissamine staining was in
relation to severity of the evaporative dry eye (as demonstrated by meibomian gland loss) and thus paralleled
increased symptomatology in these patients. This would be
in agreement with the “dry eye blepharitis syndrome
(DEBS)” theory as suggested by Rynerson and Perry, with
dry eye, blepharitis and meibomian gland dysfunction existing as one disease condition on a continuous spectrum.15
Several studies have elaborated on the inﬂuence of the
bacterial bioﬁlm, bacterial lipases, and bacterial colonization on the eyelids and within meibomian gland secretions
correlating with degree of meibomian gland dysfunction
and OSD.6,7,9,15,17,18 Our study ﬁndings reinforce prior
studies citing the prevalence of coagulase-negative staph
on the lid margin; however, it did not elucidate any signiﬁcant, nor deﬁnitive correlation between positive eyelid
margin and meibomian gland cultures and degree of
disease.6,7,8,9,15,17,18 This may in part be real or secondary
to the relatively small sample size of our study.
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The culture positivity across the meibomian gland dysfunction spectrum is in concordance with the theory
devised by Drs Rynerson and Perry, who suggested that
dry eye and blepharitis are not distinct entities but rather a
disease spectrum inﬂuenced by the bioﬁlm that forms on
the lid margin over time.9,15 We hypothesize that construction of this bioﬁlm may in fact explain the results showing
less meibomian gland dropout and superior meibomian
gland expression scores in Group A versus all other
groups.15 In addition, formation of a bioﬁlm may have
allowed for colonization with the unusual organisms seen
in our study – a ﬁnding that, to our knowledge, has not
been published previously. However, it is also important to
note that even with good culture techniques, contamination
is not an impossibility.
Throughout history, many treatments for dry eye, blepharitis, and MGD have consisted of antibiotic use (eg,
erythromycin, azithromycin, doxycycline); the presence of
a bacterial bioﬁlm on the eyelid and within meibomian
glands appears to be a reasonable treatment target.
However, we are still unsure of the impact of the bacterial
bioﬁlm on disease severity and chronicity – is it the mere
presence of bacteria, formation of bacterial lipases, invasion of meibomian glands by bacteria, and/or disruption in
normal ﬂora that is the culprit? Our study highlights and
conﬁrms the presence of bacteria (mainly CNS) across the
dry eye/MGD spectrum, and most notably, we did not ﬁnd
any correlation between culture positivity, organism type,
and dry eye diagnostic parameters.15–17
As it stands now, we are afforded many different
options as far as treatment for dry eye – from artiﬁcial
tears, to serum tears, to medications such as cyclosporine
0.05% (Restasis®, Allergan, Parsippany-Troy Hills, NJ,
USA), compounded cyclosporine, liﬁtegrast 5% (Xiidra®,
Shire, Lexington, MA, USA), even intranasal neurostimulation (TrueTear™, Allergan, Parsippany-Troy Hills, NJ,
USA).5,15 Similarly, management of blepharitis may consist of warm compresses, eyelid hygiene using saline or
medicated scrubs/sponges (eg, Avenova® [NovaBay
Pharmaceuticals Inc. Emeryville, CA, USA], OCuSOFT®
[OCuSOFT, Inc., Rosenberg TX, USA]), as well as electromechanical debridement using BlephEx ® (BlephEx,
Franklin, TN, USA).1,3,4–11,15,17,18 Adding to this is the
nutritional treatment component of oral omega-3
supplementation.1,3–10,11,15,17,18 However, with all of
these available treatments, as well as the new and evolving
available diagnostics for OSD, it is challenging to ﬁnd the
best treatment algorithm for each patient. The patients,
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who are usually uncomfortable due to their condition,
and frustrated secondary to lack of treatment efﬁcacy,
add to that challenge. Our study points out that this challenge is not easily met as signs or symptoms often do not
reﬂect clinical ﬁndings and even cultural identiﬁcation
may be of little help. Anecdotally, the authors have noted
some guidance from diagnostic tests such as MMP-9,
Schirmer 1, and lissamine green staining. MMP-9 may
be helpful in suggesting anti-inﬂammatory therapy.
Schirmer 1 being 3 or less may argue for treatment with
cyclosporine and/or punctal plugs or cautery. Lissamine
green staining may also be beneﬁcial for following
patients and evaluating the effects of treatment.
Our results pose a challenge for development of a
“universal” treatment algorithm for dry eye/MGD in
terms of targeting the microbial milieu. One may argue
MDG/OSD should be treated via eradication of the bacterial bioﬁlm – this may be accomplished by mechanical
debridement (eg, Blephex®, meibomian gland expression,
Lipiﬂow ® [TearScience®, Morrisville, NC, USA]) and/or
antibiotic use (topical or oral). In our study, 20% of all
cultures were found to be macrolide (erythromycin, speciﬁcally) resistant; whereas only 3.6% were tetracyclineresistant (all coagulase negative staph). We believe this
information is meaningful in that we should rethink the
treatment of blepharitis with antibiotics (speciﬁcally
macrolides), and perhaps make use of doxycycline (if
necessary), not necessarily for its antimicrobial effect,
but anti-inﬂammatory effect on the eyelid margin and
within meibomian glands.1,3,4,5,9,10
The bioﬁlm created by bacteria, especially staphylococcal species (S. aureus and S. epidermidis in particular –
the most prominent organisms seen in our study) is quite
strong, and may be resistant to white blood cells, antibiotics, and povidone iodine scrubs.4,15 Additionally, it has
been shown that the bacteria in the bioﬁlm can release
virulence factors (cytolytic toxins, proteases, and lipases
capable of destroying host tissue) causing escalating levels
of inﬂammation not only on the lid margin, but also on the
ocular surface, meibomian glands, and accessory lacrimal
glands.1,3,4,5,15,16,34,36 The bioﬁlm likely thickens and
diversiﬁes with age, explaining why MGD and dry eye
worsen with increasing age.4,5,11,12,15 If we cannot effectively eradicate this bioﬁlm that resides on the eyelid
margin, we cannot effectively reach the areas of the eye/
eyelids that require treatment.
Thus, perhaps our patients who are on the dry eyeblepharitis-meibomian gland dysfunction spectrum who
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are not improving on the “usual therapies” could beneﬁt
from mechanical eyelid debridement, essentially “wiping
the slate clean” to increase the efﬁcacy of therapies such as
lid hygiene, moist heat, topical sprays, and cleansers. With
its various presentations, it is easy to focus on the immediate presenting problem (eg, when a patient has meibomian
gland disease, the lash follicles may be ignored; when a
patient has lacrimal gland involvement, the meibomian
glands may be overlooked).1,4,5,6,7,15,17,37 The omnipresence of bacteria on the eyelid margins and within meibomian glands is well known, and as we noted, does not
appear to change in any particular direction across the
disease spectrum.1,2,3,5,7–11 Our data suggest that perhaps
the most important aspect of the dry eye-meibomian gland
dysfunction-blepharitis spectrum to recognize the presence, thickness and diversity of the bacterial bioﬁlm in
our patients – especially those with recalcitrant disease –
and promote its identiﬁcation among the ophthalmic community as a real entity that should be addressed or at least
considered in the formation of a treatment strategy for all
dry eye and meibomian gland disease.
Our study sought to ﬁnd association with bacterial
burden of the eyelid and meibomian glands with signs
and symptoms of OSD/meibomian gland dysfunction in a
clinic setting. Although our data provide a cross-sectional
picture of different demographics, varying presence of
bacteria, and a purported link to signs and symptoms of
OSD, there are several study limitations that require discussion. First, our small sample size limits the power of
our results, and the control group was younger (although
this was not by design). When stratifying patients based on
OSDI score and meibomian gland dysfunction, it may be
expected that this population would be younger. This
could have been potentially avoided with a larger sample
size or different stratiﬁcation techniques. However, it is
important to note that meibomian gland dysfunction is a
progressive, chronic condition, so it is not unexpected that
the asymptomatic subjects would be younger. This is a
well-known and documented ﬁnding in ophthalmic literature, albeit a signiﬁcant issue for age-match controlling.
We feel that the variables undergoing study are not themselves age dependent, but disease dependent. As we found
culture positivity to be variable across different degrees of
MGD/OSD, we must highlight that these results may be
inﬂuenced by the signiﬁcant difference in age between
Group A and the other groups, considering MGD tends
to increase with age. This could be reevaluated in a larger,
perhaps alternatively stratiﬁed study. In addition, we
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evaluated each eye independently to assess laterality as
an independent variable. Given that each subject had two
eyes, there was no confounding data or inherent bias.
Further analysis may involve the averaging of the two
eyes; however, we did not ﬁnd additional utility or
novel/unexpected results when doing so. Finally, use of
an immunosuppressant (whether topical or other) was not
part of our exclusion criteria; therefore, this may have
inﬂuenced our results as far as bacterial colonization.

Conclusions
Patients and ophthalmologists alike should understand that
meibomian gland dysfunction and related dry eye and
OSD are chronic conditions that require regular, if not
daily regimens to maintain healthy eyelids and ocular
surface.1,4,5,8,11,15 Based on our study results and others,
we can continue to use our armamentarium of diagnostic
tests to guide us in individualizing treatments – but now
with the enlightenment that addressing bacterial presence
and/or bioﬁlm aspect of these diseases may be of equal
(and in some, perhaps, more) importance in providing
efﬁcacious treatment.
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